Hims & Hers at $34: A Regulatory Bet Disguised as a Growth Story

Here is a number that should stop you before you read another bullish or bearish take on Hims & Hers: the range of Wall Street price targets on the stock runs from $12.50 to $60. The mean sits around $28. The high is nearly five times the low.

When a sell-side range is that wide, the "consensus mean" is not a consensus. It is the arithmetic midpoint of two incompatible stories told by people who mostly agree on the facts and violently disagree on what the facts imply. One camp is modeling a category-defining consumer health platform compounding toward $6 billion in revenue. The other is modeling a company whose best growth quarter may already be behind it because the product that produced that growth is about to be regulated. Averaging them produces $28, a number that describes neither future and protects no one.

This is exactly the situation where the standard retail toolkit fails. The price chart tells you HIMS went from $5 to $70 and back to the low $30s — momentum, not insight. The headline analyst rating tells you "Hold," which is what you say when you have no idea. The Reddit thread tells you it's either a 10-bagger or a zero. None of these is a second opinion. A second opinion is what a serious investor actually wants at a moment like this: not more data — there is already too much — but a grounded read that names the one question the noise is burying, lays out the evidence on both sides, and lets you decide what you believe.

So let me do that. Below is my read on Hims & Hers as of late June 2026, with the stock at $33.94. The headline: a probability-weighted fair value of $29.28, roughly 14% below the current price — a negative read, but a negative read that holds a real 30% chance the bulls are right. The interesting part is not the number. It is why the number lands where it does, and where it diverges from the Street.

I do not hold a position. Reasonable people read the same data and arrive at different conclusions.

The numbers below are as of June 2026. The live valuation, current price, updated scenario probabilities, and the underlying SEC filings and consensus data, is at dawo.ai/symbol/HIMS. If you want to override my assumptions and see how the fair value moves, the interactive sliders are there.

The question the price is actually asking

Start where every honest valuation starts: not "is it expensive?" but "what does the current price already assume?"

Run the math backward from $33.94 and the market is pricing in roughly 50% annualized revenue growth sustained over the next five years. That is an enormous number. It is below the 64.5% compound rate HIMS actually delivered from FY22 to FY25 — revenue went from $527 million to $2.35 billion — so on its face the price looks almost conservative against history. "It's growing 60%+ and the market only wants 50%, that's cheap" is a sentence a lot of bulls are saying right now, and they are not doing bad arithmetic.

The problem is that the backward-looking number and the forward-looking number are not the same business. The 64.5% historical CAGR was powered substantially by one revenue stream: mass-marketed, compounded GLP-1 weight-loss medication — the cheaper, pharmacy-compounded version of drugs like semaglutide. That stream is precisely the one now under direct regulatory threat. Extrapolating the 50% from the 64% only works if you assume the engine keeps running. The entire debate is whether it does.

The base case: the partnership replaces the engine, mostly

My base case — about a 32% probability, landing near $28 — is not a collapse. It is a handoff.

In this scenario, the FDA does restrict mass-marketed compounded GLP-1 over the course of 2026, but HIMS's partnership with Novo Nordisk to distribute branded GLP-1 at roughly $149/month ramps fast enough to catch most of the falling compounded revenue. Growth decelerates hard from 60%+ toward something more like 20-25%, the company keeps diversifying into hormone therapy, dermatology, and other recurring categories, and the multiple compresses to reflect a still-good but no-longer-hypergrowth business. You end up roughly where the stock is, give or take. Notably, this is also close to where the sell-side mean sits — the consensus is not wrong about the central path so much as it is silent about the tails. And on a name like this, the tails are the whole story.

Where I differ from consensus, and why

Here is the divergence that matters, and it is not a disagreement about the base case. It is a disagreement about the shape of the distribution around it.

I carry a fatter bear tail (38%) than the consensus range implies, and a bull case ($50, 30% weight) that sits below the most bullish analyst's $60. In other words: more downside weight, less upside conviction than the optimists. The reason is that I am not building the forward view from management's narrative or from extrapolated history. I am building it from independent, market-derived signals that consensus tends to underweight because they do not fit neatly in a model:

• Attention is already rolling over. Wikipedia pageview velocity for HIMS — a real-world proxy for consumer interest, the kind of "alt-demand nowcast" a discretionary hedge-fund desk would track and a retail platform never surfaces — is decelerating roughly 38% on a 90-day rolling basis versus the prior 90 days. That is not a number that contradicts a partnership ramp. It is a number that contradicts a continued-hypergrowth story, because hypergrowth in a direct-to-consumer business shows up as accelerating attention, and HIMS's is fading.
• Positioning is leaning into the bear. Short interest is around 28.7% of float and rising, with about 3.5 days to cover. That is the market putting real money behind the regulatory thesis — and, as I'll get to, it cuts both ways.
• The regulator named the company. In February 2026 the FDA signaled intent to restrict GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs being mass-marketed, and HIMS was named directly. This is not a vague macro risk. It is a specific, dated, company-specific catalyst.

Stack these and you get a read that consensus, anchored to the 64% history and management's framing, structurally cannot produce. The Street is averaging two stories. I'm trying to name which one the evidence currently favors — and the evidence currently favors caution.

What the bear case actually looks like

The bear case — my single largest weight at 38%, landing near $14 — is clean and specific: the FDA finalizes its restriction on mass-marketed compounded GLP-1 in the second half of 2026. The compounded revenue stream that drove the historical CAGR contracts faster than the branded Novo partnership can replace it. Growth doesn't just decelerate; it goes negative for a few quarters as the mix resets. A business being valued on 50% implied growth gets re-rated to one with a temporary air pocket, and a 38x-type multiple on falling revenue is a long way down. Fourteen dollars is roughly half the current price, and it is not a tail-risk fantasy — it is the most probable single scenario in my distribution.

What makes this bear case credible rather than alarmist is that it does not require fraud, mismanagement, or a broken business. It requires one regulator to do the specific thing it has already said it intends to do. The cleanest bear cases are the boring ones.

What the bull case looks like

I want to be equally specific about the upside, because a negative read that can't articulate the bull case isn't analysis, it's a posture.

The bull case — 30% weight, $50, meaningfully above where the stock trades — has three legs, and they're real:

1. The affordability tipping point. Novo's $149/month branded pricing undercuts peer telehealth GLP-1 offerings running $249-329. If that price unlocks a 15-25% volume lift over the base path, 2030 revenue could push toward $5.5-6 billion and sustain a premium multiple. Cheaper access to a drug everyone wants is a powerful demand unlock.
2. The partnership template repeats. Management cites two dozen active conversations with branded manufacturers. If the Novo model — HIMS as the consumer distribution layer for a branded drug — generalizes to hormone therapy, dermatology, and peptides, that's potentially $400-600 million of incremental recurring revenue by 2030, and it reframes HIMS from "compounding loophole" to "the front door for branded specialty pharma."
3. The short squeeze. 28.7% short interest with 3.5 days to cover is a lot of fuel. Any positive regulatory or earnings surprise could force covering and amplify the move toward the sell-side high.

Notice my bull case ($50) deliberately stops short of the Street's high ($60). I think the most bullish analyst is right about the direction of the affordability and template stories and too optimistic about the magnitude, given that even the bull path has to survive the regulatory transition. That's a judgment, not a fact, and you are welcome to weight it differently — which is rather the point.

The variant perception worth holding

If I had to compress the whole thing into one sentence a portfolio manager would actually act on: the growth that justifies the multiple and the growth that's under regulatory threat are the same growth. Consensus is implicitly treating them as separable — modeling continued compounding while waving at "regulatory risk" as a footnote. They are not separable. The compounded-GLP-1 mix is the hypergrowth. Price in the FDA's stated intent honestly and the central estimate has to sit below today's price, not above it.

That's the read. It is a negative one. It is also not a recommendation, and the distinction matters more than it sounds.

What would change my mind

I'm building this on a 12-month horizon. Here is what would move it.

Toward more bullish: The FDA restriction lands narrower than feared (e.g. enforcement discretion that spares HIMS's specific formulations), or the Novo branded ramp shows up in a print with branded GLP-1 already replacing compounded dollars one-for-one. Either moves me from $29 expected toward the high $30s and would pull the bear weight down materially.

Toward more bearish: A finalized, broad FDA restriction with a hard 2026 effective date, or a Wikipedia/search-attention deceleration that accelerates rather than stabilizes, or a quarter where subscriber net-adds turn negative. Any of these moves the central estimate toward the low $20s and the bear case from "most probable" to "base."

Toward "no view": A messy in-between where the restriction passes but the Novo ramp simultaneously surprises to the upside — the compounded engine dies and the branded engine fires at the same time. That's a genuinely two-sided outcome I would not want to hold strong conviction on until a couple of prints clarify which force is bigger. On a name this binary, "I don't have a view yet" is a legitimate and underrated position.

A note on conviction

My conviction here is moderate, not high — appropriately, for a stock whose fair-value distribution runs from $14 to $50. The honest summary is: the expected value is below the price, the most probable single scenario is the bear, and the upside scenario is real and large enough that shorting this is its own kind of bet. That is a coherent negative read, not a coherent short thesis. The two are different things.

The asset to be most suspicious of in this analysis is the assumption that the Novo branded ramp scales smoothly across product categories. The cross-vertical attach data is thin, the cohort is still young, and management's framing about "two dozen active partnership conversations" is the kind of forward-looking color that earnings calls reward and reality does not always deliver on. If two consecutive quarters show branded ramp materially exceeding compounded decline — particularly with cross-vertical attach holding above 25% — the central estimate moves up toward the mid-$30s and the bear weight drops toward 25%.

If they don't, the central estimate moves toward the low $20s and the bear case stops being the most probable scenario and starts being the base.

That's the read. I'd rather be transparent about where I could be wrong than offer a clean number.

This is research, not personalized investment advice. I do not hold a position in HIMS at the time of writing. Past performance does not guarantee future results. Price and analysis as of June 29, 2026; HIMS at $33.94.

Goutam Mahapatra is the founder of Dawo, a second-opinion research engine that runs this kind of grounded, scenario-weighted analysis across the stocks you actually own — then tells you when the facts change. He was previously Head of Marketplace at Uber Eats EMEA. Reach him at goutam@dawo.ai.